HONG KONG – China-based ophthalmology startup Ocumension Therapeutics Ltd. has inked a deal for potentially €36.25 million (US$41.35 million) to develop and commercialize French counterpart Nicox SA's NCX470 in the Chinese mainland, Hong Kong, Macau and Taiwan.
